Proteomics International Laboratories Ltd (ASX:PIQ) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-anal
Perth, Western Australia
- Tweets 788
- Following 64
- Followers 181
- Likes 68
@ProteomicsI is proud to be recognised as one of Australia’s Top Diabetes Innovators in @DiabetesAus's Grand Innovation Challenge. The Showcase Pitch Event is Tuesday 18 August 3pm in Melbourne.
Register your spot at: ow.ly/wkyw50ZrAC8
21
@ProteomicsI International signs national distribution agreement with Healius for Promarker® portfolio.
Please find the full announcement here: tinyurl.com/distribution-agr…
31
We're excited to announce that @ProteomicsI International has been selected as a Finalist in the 2026 @DiabetesAus Grand Innovation Challenge!
Our project showcases Promarker®D, our predictive blood test designed to identify diabetes-related kidney disease risk before onset.
2
3
112
ANNOUNCEMENT: New publication!
Our latest peer-reviewed study in PharmacoEconomics – Open shows the potential health-economic value of #PromarkerD in managing CKD in people with #Type2Diabetes.
View here: proteomics.com.au/promarkerd…
2
2
69
Congratulations to Professor Timothy Davis on being appointed an Officer of the Order of Australia (AO) in the 2026 King’s Birthday Honours for distinguished service to medicine, clinical research (diabetes) and infectious diseases.
1
2
38
We are deeply saddened by the passing of Professor Ele Ferrannini, a visionary scientist who transformed the treatment of diabetes.
As a member of the Promarker®D Clinical Advisory Board, his expertise contributed to improving the prediction of chronic kidney disease.
36
We're shifting focus to commercialising our diagnostic tests. With ongoing innovation, a distributor-driven rollout, and new leadership, we’re ready for growth, reimbursement, and global expansion.
View article: theage.com.au/business/compa…
2
26
We’re pleased to see Proteomes (MDPI) publish an interview with Dr Scott Brigans, Head of Research at @urn:li:organization:2377372, discussing recent work in blood‑based diagnostics for oesophageal cancer.
mdpi.com/journal/proteomes/a…
32
Endometriosis affects 1 in 9 women, yet diagnosis takes years.
We're hosting an education evening for healthcare professionals on 26 March focused on practical management & triage in primary care.
Free event. CPD applicable. Webinar available.
Register: tinyurl.com/MarchEndoGPEvent
65
Australia goes RED for World Kidney Day.
Landmarks across the country were illuminated RED as part of the national awareness initiative led by @KidneyHealth Australia to highlight the growing impact of chronic kidney disease.
#WorldKidneyDayAU #KHA #KidneyCodeRed
97
World Kidney Day highlights the impact of chronic kidney disease in Australia.
Proteomics International has researched protein biomarkers associated with kidney disease risk, including clinical evaluation of the Promarker®D assay.
#WorldKidneyDay #KidneyCodeRed #Awareness
46
Recent stories in the media have been deeply distressing for many in the endometriosis community. We acknowledge how difficult it can be to read or hear accounts of painful experiences and concerns about care, and we recognise the courage of those who have shared their stories.
23
High-plex discovery is easy. Clinical translation is the challenge.
Promarker® supports biomarker validation for clinical research using targeted mass spectrometry assays, quantitative data, and ISO-accredited laboratory workflows.
Enquire here: proteomics.com.au/submit-you…
54
We’re pleased to appoint David Morris as CEO & Managing Director of Proteomics International Laboratories Ltd (ASX: PIQ), effective 19th Jan 2026.
David brings deep global MedTech leadership as we accelerate commercialisation of the Promarker® pipeline.
41
Proteomics International secures Canadian patent for breakthrough esophageal cancer blood test.
Patents now cover: 🇺🇸 🇨🇦 🇪🇺 🇦🇺 🇨🇳 🇭🇰
90% of EAC cases are detected too late. This test is a game-changer for early diagnosis.
Full details: investor.proteomics.com.au/i…
29
Media coverage this week has highlighted Proteomics International’s proteomics-based testing approaches for assessing diabetic kidney disease risk, including their relevance to Indigenous communities.
More info: proteomics.com.au/promarkerd…
Article: smh.com.au/business/companie…
1
38
Firefighters face a 62% higher risk of esophageal cancer. This is a public health crisis.
Early detection matters. Promarker®Eso is part of our commitment to advancing predictive diagnostics for high risk communities.
Story: abc.net.au/news/2025-12-10/v…
26
🧪 C-Terminal Lysine Truncation in Antibodies
Sensitive MS-based quantification of C-terminal lysine loss on mAbs—supporting batch consistency & biosimilar comparability, aligned with ICH Q6B.
🔗 hubs.la/Q03Y6lMg0
#Biologics #Biosimilars #MassSpectrometry
1
1
39
Let Us Do the Proteomics for you
Advance your precision medicine projects with:
✔️ Biomarker discovery
✔️ PK+Biomarker Validation
✔️ Clinical-grade proteomic insights
👉 You focus on the science — we’ll handle the proteomics.
#Proteomics #Biomarkers #MassSpec #DrugDevelopment
1
1
74
Proteomics International retweeted
Medtech company @ProteomicsI has landed a major US breakthrough, with Medicare setting a US$390.75 reimbursement price for its next-gen #PromarkerD kidney disease test, paving the way for national clinical uptake.
$PIQ #BULLSNBEARSWA #ASX @smh
smh.com.au/business/companie…
1
3
330